Trials / Unknown
UnknownNCT01675219
Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)
Treatment of Ta Bladder Cancer in High Risk of Recurrence - Fluorescence Cystoscopy With Optimized Adjuvant Mitomycin-C (FinnBladder 9)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Turku University Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Bladder cancer (BC), the second most common urological malignancy, is an important public health issue. One of the main challenges in the treatment of bladder cancer if the prevention of recurrences of non-invasive tumors, which is also associated with significant costs. The current study will investigate optimal treatment of patients with bladder cancer with high risk of tumor recurrence but low risk of progression. The main interest is comparison of photodynamic (PDD) bladder tumor resection (TUR-BR)to traditional TUR-BT. Also the efficacy of adjuvant optimized mitomycin-C is compared to patients with no adjuvant treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | white light TUR-BT | traditional transurethral bladder tumor resection |
| PROCEDURE | blue light TUR-BT | photodynamic transurethral bladder tumor resection |
| DRUG | optimized MMC | six weekly optimized mitomycin-C instillations |
| DRUG | single immediate chemotherapy instillation | single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2021-12-01
- Completion
- 2023-08-01
- First posted
- 2012-08-29
- Last updated
- 2023-04-13
Locations
10 sites across 1 country: Finland
Source: ClinicalTrials.gov record NCT01675219. Inclusion in this directory is not an endorsement.